This trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help treat triple negative breast cancer.
- Breast Cancer
1 Primary · 2 Secondary · Reporting Duration: Following definitive surgery, approximately 9 months.
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
12 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To which illnesses is Pembrolizumab typically prescribed?
"Pembrolizumab is frequently used to help patients with malignant neoplasms, particularly in cases of unresectable melanoma or where chemotherapy has failed. It can also assist those suffering from microsatellite instability high conditions." - Anonymous Online Contributor
Has Pembrolizumab been evaluated in earlier experiments?
"Currently, there are 964 ongoing studies for pembrolizumab with 122 of them in Phase 3. Primarily based in Houston, TX., this medication has been tested at over 35 thousand locations worldwide." - Anonymous Online Contributor
Is recruitment for this research endeavor still available?
"This clinical trial, which has been available since the 30th of December 2020 and was last amended on the 31st of January 2022 is actively seeking participants." - Anonymous Online Contributor
What has been the outcome of regulatory consideration for Pembrolizumab?
"Our team has assigned Pembrolizumab a safety rating of 2, as there is some evidence that it does not pose substantial risk to patients, but data supporting its efficacy in this particular Phase 2 trial remains inconclusive." - Anonymous Online Contributor
Can you provide an estimate of the total cohort size for this research study?
"Affirmative. Clinicaltrials.gov verifies that this experiment is actively searching for participants; the original post was created on December 30th 2020 and edited most recently on January 31st 2022. The research requires a total of thirty patients from one specified medical site." - Anonymous Online Contributor